NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) — Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the second quarter ended June 30, 2021.
“During the second quarter and year to date, we made important progress towards advancing PT00114 into the clinic, in order to treat stress-related neuropsychiatric disorders which afflict a growing patient population,” said Dr. Garo Armen, Executive Chairman of Protagenic Therapeutics. “We have a clear clinical path toward major indications. We anticipate rapid efficacy and safety readouts in the first half of 2022.”
Anticipated Upcoming Milestones
Q4 2021: Re-filing of IND application for PT00114
Q1 2022: Initiation of Phase I/IIa study for PT00114
1H 2022: Initial Data Readout of Phase I/IIa study
Financial Results for the Second Quarter Ended June 30, 2021:
Net loss attributable to common stockholders for the quarter ended June